ProQR Therapeutics N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRQR research report →
Range $3 – $3
Price Chart
About the company
ProQR Therapeutics N. V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders.
- CEO
- Daniel Anton de Boer
- IPO
- 2014
- Employees
- 166
- HQ
- Leiden, ZH, NL
Get TickerSpark's AI analysis on PRQR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $146.77M
- P/E
- -2.73
- PEG
- -0.25
- P/S
- 7.11
- P/B
- 1.69
- EV/EBITDA
- -1.50
- Div Yield
- 0.00%
- Gross Margin
- 93.16%
- Op Margin
- -216.56%
- Net Margin
- -210.65%
- ROE
- -70.45%
- ROIC
- -48.90%
Latest fiscal year · YoY change
- Revenue
- $15.28M-19.2%
- Gross Profit
- $12.68M-32.9%
- Op Income
- $-42,154,897
- Net Income
- $-40,519,110-45.9%
- EPS
- $-0.38-11.8%
- OCF Growth
- -45.1%
- FCF Growth
- -42.3%
- 52W High
- $2.49
- 52W Low
- $1.00
- 50D MA
- $1.50
- 200D MA
- $1.67
- Beta
- 0.03
- RSI (14)
- 31
- Avg Volume
- 790.60K
No earnings-call transcripts are available for PRQR yet.
- Free Float
- 64.8%
- Shares Outstanding
- 141.12M
- Float Shares
- 91.44M
of shares held by institutions
71 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aberdeen Group PLC | 9.67M | ▲ 735.05K |
| Adage Capital Partners Gp, L.L.C. | 9.02M | ▲ 2.76M |
| Privium Fund Management B.V. | 5.47M | ▼ 52.88K |
| Affinity Asset Advisors, LLC | 4.97M | ▼ 573.86K |
| Ikarian Capital, LLC | 3.43M | ▲ 1.93M |
| Woodline Partners LP | 3.28M | ▲ 3.28M |
| Heights Capital Management, Inc | 2.76M | ▲ 2.76M |
| Sphera Funds Management Ltd. | 1.76M | ▲ 1.76M |
| Kynam Capital Management, LP | 1.57M | 0 |
| Dafna Capital Management LLC | 1.53M | ▼ 37.20K |
| Squadron Capital Management LLC | 1.51M | ▲ 1.51M |
| Morgan Stanley | 1.41M | ▼ 356.67K |
Held by 16 ETFs
Biggest fund positions in PRQR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | de Boer Daniel Anton | buy | 200,000 |
| Jul 17, 26 | Filius Bart | buy | 150,000 |
| Jul 9, 26 | de Boer Daniel Anton | buy | 150,000 |
| Jul 7, 26 | de Boer Daniel Anton | buy | 150,000 |
| Jun 2, 26 | Hinsch Gylvin Lykke | other | 14,595 |
| Jun 26, 26 | Filius Bart | buy | 150,000 |
| Jun 2, 26 | Hinsch Gylvin Lykke | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRQR coverage
Recent articles, reports, and earnings notes.
No research on PRQR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRQR report →ProQR Announces Third Quarter 2026 Operating and Financial Results
globenewswire.com · Nov 12
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
globenewswire.com · Oct 28
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts
defenseworld.net · Oct 18
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
marketbeat.com · Oct 2
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
seekingalpha.com · Sep 30
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
globenewswire.com · Sep 23
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
globenewswire.com · Sep 9
ProQR to Participate in Upcoming Investor Conferences in September 2026
globenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.